BioCentury | Aug 22, 2020
Translation in Brief
IPD’s synthetic bio unlocks target combos for cell therapy; plus Merck’s oral STING agonist, Surrozen’s regenerative therapy and more
...of T cells in conferring long-term immunity against SARS-CoV-2. TARGETSASGR1 (ASGPR; CLEC4H1) – Asialoglycoprotein receptor 1 LGR5 (GPR49...